177Lu-DOTATATE (177Lu) efficacy in metastatic well-differentiated neuroendocrine tumors (wdNET): Differences in response according to metastases (met) location

#4161

Introduction: Treatment with 177Lu is standard of care for wdNET with high somatostatin receptor expression. Patterns of response could differ between hepatic (hep) and extrahepatic (ehep) met.

Aim(s): The aim of this work is to assess the tumor growth rate (TGR) before and after 177Lu and to compare the depth of response in hep versus (vs) ehep met.

Materials and methods: Data of 68 patients (pts) treated from 2017 to 2022 were retrospectively collected. Of 56 evaluable pts, 15 had liver-only (LO) and 41 liver and ehep (LE) met. Tumor response was assessed with RECIST 1.1. TGR was calculated globally and separately in both subgroups, pre- and post-177Lu. The t-test was used to contrast hypotheses. Statistical analysis was done with RStudio v2023.

Conference:

Presenting Author:

Authors: Sánchez Gómez L, Guillén Sentís P, Ruffinelli J, Torrent F, Vercher Conejero J,

Keywords: 177lu-dotatate, well-differentiated neuroendocrine tumor, tumor growth rate,